Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal Bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctuate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143: 977–983
Gonzales C (1992) Serous retinal detachment. Value of acetazolamide. J Fr Ophthalmol 15: 529–536
Haimovici R, Koh S, Gagnon DR et al. Central Serous Chorioretinopathy Case Control Study Group (2004) Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111: 244–249
Holz FG (2000) Akute und chronische idiopathische Chorioretinopathia centralis serosa. In: Kampik A, Grehn F (Hrsg) Augenärztliche Differentialdiagnose. Thieme, Stuttgart
Jonas JB, Kamppeter BA (2005) Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol 89: 386–387
Klatt C, Elsner H, Pörksen E et al. (2006) Selektive Retina-Therapie bei Retinopathia centralis serosa mit Pigmentepithelabhebung. Ophthalmologe 103: 850–855
Koh AHC (2006) Photodynamic therapy for focal RPE leaks. Ophthalmology 11: 2110.e1–2110.e3
Mennel S, Barbazetto I, Meyer CH et al. (2007) Ocular photodynamic therapy standard applications and new indications (part 2). Review of the literature and personal experience. Ophthalmologica 221: 282–291
Otsuka S, Ohba N, Nakao K (2002) A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina 22: 25–32
Tittl MK, Spaide RF, Wong D et al. (1999) Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 128: 63–68